TY - JOUR
T1 - NCCN Task Force report
T2 - optimal management of patients with gastrointestinal stromal tumor (GIST)--expansion and update of NCCN clinical practice guidelines.
AU - Demetri, George D.
AU - Benjamin, Robert
AU - Blanke, Charles D.
AU - Choi, Haesun
AU - Corless, Chris
AU - DeMatteo, Ronald P.
AU - Eisenberg, Burton L.
AU - Fletcher, Christopher D.M.
AU - Maki, Robert G.
AU - Rubin, Brian P.
AU - Van den Abbeele, Annick D.
AU - von Mehren, Margaret
AU - NCCN GIST Task Force, GIST Task Force
PY - 2004/5
Y1 - 2004/5
N2 - NCCN's Sarcoma Clinical Practice Guidelines in Oncology include a subsection regarding treatment recommendations on gastrointestinal stromal tumors (GISTs). GIST is one area of medicine where the standard of practice has been affected rapidly and dramatically by the introduction of effective molecularly targeted therapy for this disease. There are few examples in modern medicine in which the implementation of new technologies into practice has so radically and rapidly affected clinical diagnostic strategies and treatments with significant implications for the care of patients. Because of these recent changes, NCCN organized a broad multidisciplinary panel composed of experts in the fields of diagnostic radiology, pathology, molecular diagnostics, surgery, medical oncology, and radiation oncology to discuss the optimal approach for the care of patients with GIST at all stages of the disease. The GIST task force is composed of NCCN faculty and other key experts from North America, comprising the United States and Canada. The purpose of this meeting was to expand on the existing NCCN clinical practice guidelines for gastrointestinal sarcomas and to identify areas of future research to optimize our understanding and treatment of this disease.
AB - NCCN's Sarcoma Clinical Practice Guidelines in Oncology include a subsection regarding treatment recommendations on gastrointestinal stromal tumors (GISTs). GIST is one area of medicine where the standard of practice has been affected rapidly and dramatically by the introduction of effective molecularly targeted therapy for this disease. There are few examples in modern medicine in which the implementation of new technologies into practice has so radically and rapidly affected clinical diagnostic strategies and treatments with significant implications for the care of patients. Because of these recent changes, NCCN organized a broad multidisciplinary panel composed of experts in the fields of diagnostic radiology, pathology, molecular diagnostics, surgery, medical oncology, and radiation oncology to discuss the optimal approach for the care of patients with GIST at all stages of the disease. The GIST task force is composed of NCCN faculty and other key experts from North America, comprising the United States and Canada. The purpose of this meeting was to expand on the existing NCCN clinical practice guidelines for gastrointestinal sarcomas and to identify areas of future research to optimize our understanding and treatment of this disease.
KW - Combined Modality Therapy
KW - Diagnosis, Differential
KW - Gastrointestinal Neoplasms/diagnosis
KW - Gastrointestinal Stromal Tumors/diagnosis
KW - Humans
KW - Immunohistochemistry
KW - Positron-Emission Tomography
KW - Practice Guidelines as Topic
KW - Tomography, X-Ray Computed
UR - http://www.scopus.com/inward/record.url?scp=84879133032&partnerID=8YFLogxK
M3 - Article
C2 - 23573667
AN - SCOPUS:84879133032
SN - 1540-1405
VL - 2 Suppl 1
SP - S-1-26; quiz 27-30
JO - Journal of the National Comprehensive Cancer Network : JNCCN
JF - Journal of the National Comprehensive Cancer Network : JNCCN
ER -